Objective: To evaluate differences in glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV patients on HAART (highly active antiretroviral therapy) presenting with and without lipodystrophy as well as in drug-naïve HIV patients using FDG PET.
INTRODUCTION
Many patients infected with the human immunodeficiency virus (HIV) treated with highly active antiretroviral therapy (HAART) develop a syndrome, termed lipodystrophy, that is similar to the central/visceral obesity-insulin resistance syndrome which is characterized by a shift in body fat distribution to the central abdominal region, insulin resistance, hyperinsulinemia, dyslipidemia and in some, type 2 diabetes (1,2).
The underlying cause of the lipdoystrophy syndrome in HIV-patients on HAART is currently unclear. One theory is that HAART interferes with the body's processing of fat.
Lipodystrophy in HIV-infected patients is characterized by subcutaneous fat atrophy and visceral fat accumulation (3, 4) . Some degree of apoptosis, in the absence of significant inflammatory phenomena, occurs in subcutaneous adipocytes from patients on HAARTassociated lipodystrophy, providing evidence for a possible mechanism of subcutaneous adipocyte loss in these patients (5) . Apoptosis is an energy dependent phenomenon that is accompanied by increased FDG utilization as evidenced by tumour xenograft models (6,7).
Another theory is that insulin resistance plays a causative role in lipodystrophy (8,9,10).
Glucose transport is a critical step for insulin-stimulated glucose utilization in skeletal muscle.
The process of insulin-stimulated glucose transport requires the movement of intracellular G glucose-transporter 4 (GLUT4) -rich vesicles to the cell surface, accompanied by translocation of additional vesicular cargo proteins. Several reports in animals indicate that HAART can decrease the intrinsic activity of the glucose transporter GLUT-4, resulting in insulin resistance and a decrease of glucose uptake by skeletal muscle tissue (11) . Insulin resistance by skeletal muscle cells will result in hyperinsulinemia and hyperinsulinemia was noted to be associated with obesity already shortly after the development of the assay for insulin. Since than, this association has been confirmed with the hyperinsulinemic-euglycemic clamp and with the frequently sampled intravenous glucose tolerance test.
18-Fluorodeoxyglucose (FDG) positron emission tomography (PET) is a well validated technique to image and measure uptake of glucose in normal tissues, cancer and inflammatory lesions. In this study, FDG PET was used to assess differences in glucose uptake by skeletal Images were acquired in a 3-dimensional mode and reconstructed with and without attenuation correction (CT-based) using OSEM (ordered subset expectation maximization) yielding axial, sagittal and coronal slices. FDG SUV mean values of thigh muscle and subcutaneous abdominal fat (belly, supra-umbilical) were derived from the reconstructed PET images using square regions of interest positioned based on the CT-scan findings. Regions of interest positioning was performed by two nuclear medicine specialist blinded to the clinical and biochemical data. Averaged data were used for further analysis.
Statistical analysis
Statistical analysis was performed using SPSS version 15.0.
Correlation analysis was performed using the non-parametric Spearman-rank test. Normality was assessed using the Kolmogorov-Smirnov test.
Differences in the variables studied between the three groups under study were assessed by means of the Kruskal-Wallis test and additional Mann-Whitney testing considering p-values inferior to 0.01 as statistically significant in order to correct for multiple comparisons. Median values for viral load (copy number/mL) and CD4 cell count (/mL) were respectively 457000/mL(range: 223458-532175 /mL) and 59/mL(range: 53-117/mL) in therapy naïve patients, 972/mL(range: 50-321543/mL) and 256/mL(range: 50-524/mL) in treated patients without lipodystrophy and 188/mL(range: 50-154234/mL) and 256/mL(range: 53-542/mL) in treated patients with lipodystrophy.
RESULTS

Patient
SUV mean values of subcutaneous fat were not significantly different between therapy-naïve patients and patients under HAART that did not present with lipodystrophy. In contrast, SUVmean values of subcutaneous fat were significantly higher in patients under HAART presenting with lipodystrophy when compared to both other groups (p=0.0001)(also see 
DISCUSSION
This study aimed to assess potential differences in quantitative FDG uptake by skeletal muscle tissue and subcutaneous fat in HIV patients on HAART presenting with and without lipodystrophy as well as in .drug-naïve HIV patients.
Based on data derived from light microscopic and ultra-structural observations in a limited number of HIV-patients under HAART, some authors have suggested that lipo-dystrophy results from replacement of white fat by brown fat , which is highly FDG (12,13,14,15) . (17, 18) . In line with these findings, using visual analysis of FDG PET images a significant reduction of FDG uptake was observed in three patients in whom stavudine was replaced by the less mitochondrial toxic zidovudine, abacavir or tenovir by Bleeker-Rovers et al (19) . Their and our findings taken together suggest that FDG PET may allow for quantitative non-invasive monitoring of lipo-atrophy of subcutaneous fat during the course of HIV treatment using currently available treatment options but especially novel treatment options aimed at reducing lipodystrophy and insulin-resistance.
Behrens et al previously aimed to identify possible defects in skeletal muscle glucose uptake and metabolism in HIV patients receiving HAART using a combination of the euglycemichyperinsulinemic clamp technique, indirect calorimetry and dynamic FDG PET imaging of the thighs (20) . Whole-body glucose disposal was significantly reduced in patients presenting with lipodystrophy when compared with untreated patients. Reduced skeletal glucose uptake was caused by significantly impaired glucose transport and phosphorylation; skeletal muscle glucose uptake was reduced by 66% in treated patients when compared to therapy-naive patients. Contrary to these findings obtained under insulinic stress, available preclinical data suggest that under basal conditions, HAART increases rather than decreases glucose uptake of skeletal muscle cells (21) . More specifically, both saquinovir, indinavir, ritonavir and amprenavir at a concentration of 10 µM were shown to nearly double the uptake of 2-deoxyglucose of L6 myoblasts under basal conditions. Our findings, however, do not corroborate these preclinical findings; identical levels of FDG uptake were found in untreated and treated patients, either presenting with our without lipodystrophy. 1b
